Thursday, July 2, 2026 See who Washington just made rich Go Pro · $40/mo →
Money Racket
Who Cashes In When Washington Moves
DEFENSEThe F-35 Sustainment Lock-In: Why the Pentagon's Most Expensive Program Keeps Paying One Company ForevertodayHEALTHCARE340B Under Fire: The Hospital Drug Discount Fight That Hits CVS and HCA Where It Hurts4 weeks agoTRADE & TARIFFSThe Tariff Refund Portal Is Open and Companies Are Cashing In — Nike and FedEx Are the Names to WatchyesterdayHEALTHCAREGLP-1 Coverage Mandate: The Federal Obesity Drug Windfall for Lilly and Novo4 weeks agoMARKETSSupreme Court Gives Trump FTC Firing Power — Antitrust Enforcement Just Got More PoliticalyesterdayHEALTHCAREFDA Accelerated Approval Reform: The Vertex Model Every Biotech Wants4 weeks agoTRADE & TARIFFSTrump's Fertilizer Tariff Suspension Cuts Input Costs for Farmers — and Squeezes Domestic ProducersyesterdayHEALTHCAREThe Medicare Drug Negotiation Trade: Who Gets Hurt When Washington Sets the Price4 weeks agoDEFENSEThe Nuclear Triad Upgrade Cycle: Three Legs, Three Winners, Decades of Locked-In SpendingyesterdayCRYPTOThe Anti-CBDC Play: No Digital Dollar Means Private Rails Win4 weeks agoDEFENSEWhen the Pentagon Classifies a Budget Line: The Black Budget Trade2 days agoCRYPTOThe Toll Booth at the Top of the Bitcoin ETF Stack4 weeks agoDEFENSENATO's 2% Mandate Is a Revenue Stream Disguised as an Alliance Obligation3 days agoCRYPTOThe IRS Closes the Crypto Wash-Sale Loophole — and Robinhood Collects the Toll4 weeks agoDEFENSEThe Drone Proliferation Trade: Washington's Shift to Attritable Unmanned Systems Creates a Recurring Revenue Stream3 days agoCRYPTOThe Debanking Era Is Over. HOOD and Block Are Next in Line at the Window.4 weeks agoDEFENSEThe Hypersonic Arms Race Has a Bottleneck — and Three Contractors Own It4 days agoCRYPTOMining the Grid: How EPA and Energy Policy Set the Spread for Proof-of-Work Miners3 weeks agoDEFENSEThe Pentagon's AI Mandate: Why Defense Data Platforms Are Now a Weapons Program5 days agoCRYPTOThe Stablecoin Bill: Who Controls the On-Ramp When Congress Licenses It3 weeks agoDEFENSEIron Dome and the FMS Pipeline: How Middle East Tensions Fund Missile Defense Primes5 days agoCRYPTOBitcoin as Reserve Asset: The Federal Legitimacy Trade3 weeks agoENERGYThe SPR Refill Trade: Who Gets Paid When Washington Buys Oil6 days agoCRYPTOThe SEC Retreat: How a Friendlier Regulator Unlocks Coinbase's Business Model3 weeks agoENERGYLNG Export Licenses: How a FERC Approval Mints a Monopolylast weekTECHThe Federal Data Center Mandate: How Washington's AI Spending Flows to Hardware3 weeks agoENERGYThe BLM Calendar That Moves COP and OXYlast weekTECHThe Domestic Equipment Play: How Foreign Chip Tool Restrictions Hand Applied Materials a Structural Edge3 weeks agoENERGYThe Permian Methane Rule: Why Stricter EPA Standards Are a HAL and SLB Giftlast weekTECHThe AI Diffusion Rule Is Picking Winners Inside the Chip Stack — and It Is Not Who You Think3 weeks agoENERGYThe Permit Logjam Is Breaking: Williams and Kinder Morgan Hold the Keyslast weekTECHThe HBM Monopoly: How Federal Memory Standards Lock In Micron3 weeks agoENERGYThe Tax Code Oil Patch: Who Gets Crushed If Washington Kills the IDC Deductionlast weekTECHThe Tariff Arbitrage: How Chip Import Duties Reshape the Foundry Map3 weeks agoENERGYThe Pipe Tax: How Section 232 Steel Tariffs Rewire U.S. Drilling Economicslast weekTECHThe Chip Stack Below the Pentagon's AI Buildup3 weeks agoENERGYSanctions Relief and the LNG Arbitrage: When State Department Decisions Move the Henry Hublast weekTECHThe CHIPS Act Subsidy Ladder: Who Actually Receives the $39 Billion3 weeks agoENERGYThe Nuclear Production Tax Credit Trade: Who Gets Paid to Keep Old Reactors Alivelast weekENERGYThe Grid Hardening Bill Trade: How Federal Transmission Investment Lifts the Equipment Makers2 weeks agoENERGYThe Uranium Supply Squeeze: How the Russian Import Ban Flows to Cameco and Centruslast weekTECHThe Export Control Squeeze: BIS Chip Rules Are Splitting the AI Hardware Market in Two2 weeks agoENERGYThe SMR Funding Funnel: How DOE's Loan Billions Flow to Small Modular Reactorslast weekENERGYThe Only U.S. HALEU Cascade: How Centrus Became the Gatekeeper to the Advanced Reactor Boom2 weeks agoENERGYWashington Plugs AI Into Reactors: The Behind-the-Meter Nuclear Offtake Trade2 weeks agoENERGYThe Grid Reliability Mandate: FERC's Capacity Market Rules Are Writing Checks to Nuclear2 weeks agoENERGYThe Nuclear Restart Order: Only One Operator Has Actually Flipped the Switch2 weeks ago
Markets & Filings

FDA Approval / Recall

The FDA's green light to sell a product, or its order to pull one, both swing healthcare stocks hard.

Also known as: FDA Decision, Market Authorization

What it is
FDA approval authorizes a drug, biologic, or device for U.S. marketing after review of safety and efficacy. A recall removes a product from the market over safety concerns. Both are formal regulatory actions with immediate commercial consequences.
How it moves markets
Approval opens a revenue stream and can validate a platform, lifting the sponsor; a recall or safety action destroys sales and invites litigation. Investors trade the binary outcome and the follow-on market-size debate. Label breadth and competition shape the reaction.
Track record
Approvals of blockbuster therapies have repriced entire treatment categories, while high-profile recalls have wiped out product-line revenue.
Who it affects
Pharma and device names like PFE, LLY, MRK, MDT; ETFs XBI, IBB.
Related terms
pdufa-date, drug-price-negotiation, event-driven
Common misread
Approval is not adoption; a narrow label, pricing pushback, or reimbursement gaps can starve a launch.
Watch out for
The stock may fade after the pop as investors debate real-world uptake.
General information, not medical advice. Ingredient effects vary by formulation, concentration, and skin. Patch-test new actives and consult a qualified provider before starting prescription ingredients.

More markets & filings

Know what's coming before your patients ask for it.

New actives, device launches, and the FDA calls that change what you can offer — distilled into a two-minute brief, twice a week. Money Racket Pro.

Go Pro · $40/mo
Money Racket Pro

By the time it's news, the money's already moved.

The contract award, the executive order, the tariff cut — it mints winners before the financial press connects the dots. Pro gets you there first: what happened, who cashes in, and exactly what to watch — in a two-minute read.

Go Pro · $40/mo The policy-to-profit brief. Cancel anytime.
The pre-market brief · Mon–Sat, 7:45am ET Go Pro · $40/mo →